Patents by Inventor Gerd Wohlfahrt

Gerd Wohlfahrt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS
    Publication number: 20180312496
    Abstract: The invention relates to novel bicyclic heterocycle derivatives of formula (I) wherein Cy1, Cy2, R1, R2, and L1 have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful as bromodomain inhibitors in the treatment or prevention of diseases or disorders where bromodomain inhibition is desired.
    Type: Application
    Filed: June 30, 2016
    Publication date: November 1, 2018
    Inventors: Susanta SAMAJDAR, Chandrasekhar ABBINENI, Tero LINNANEN, Gerd WOHLFAHRT
  • PROTEIN KINASE INHIBITORS
    Publication number: 20180250272
    Abstract: A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (1) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.
    Type: Application
    Filed: May 7, 2018
    Publication date: September 6, 2018
    Inventors: Tero LINNANEN, Gerd WOHLFAHRT, Srinivas NANDURI, Ravi UJJINAMATADA, Srinivasan RAJAGOPALAN, Subhendu MUKHERJEE
  • SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS
    Publication number: 20180186739
    Abstract: The present invention provides novel spiro[cyclobutane-1,3?-indolin]-2?-one derivatives of formula (I) in which Cy, R1, R2, R4, L, and m have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful as bromodomain inhibitors in the treatment or prevention of diseases or disorders where bromodomain inhibition is desired.
    Type: Application
    Filed: June 15, 2016
    Publication date: July 5, 2018
    Inventors: Ravi Kotrabasaiah UJJINAMATADA, Susanta SAMAJDAR, Chandrasekhar ABBINENI, Subhendu MUKHERJEE, Tero LINNANEN, Gerd WOHLFAHRT
  • CYP17 inhibitors/antiandrogens
    Patent number: 9890139
    Abstract: Compounds of formula (I) wherein R1 to R8, A, B, Z1, and Z2 are as defined in the claims and pharmaceutically acceptable salts and esters thereof are disclosed. The compounds of formula (I) possess utility as androgen receptor antagonists (inhibitors) and/or cytochrome P450 monooxygenase 17?-hydroxylase/17,20-lyase (CYP17) inhibitors. The compounds are useful as medicaments in the treatment of cancer, particularly prostate cancer, and other androgen dependent conditions and diseases where androgen antagonism is desired.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: February 13, 2018
    Assignee: ORION CORPORATION
    Inventors: Gerd Wohlfahrt, Petteri Rummakko, Arja Karjalainen, Mikko Passiniemi, Pekka Pietikäinen, Anssi Haikarainen, Emilia Väisänen, Eija Tiainen
  • ANDROGEN RECEPTOR MODULATING COMPOUNDS
    Publication number: 20170260206
    Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: April 13, 2017
    Publication date: September 14, 2017
    Inventors: Gerd WOHLFAHRT, Olli TÖRMÄKANGAS, Harri SALO, lisa HÖGLUND, Arja KARJALAINEN, Pia KOIVIKKO, Patrik HOLM, Sirpa RASKU, Anniina VESALAINEN
  • Androgen receptor modulating compounds
    Patent number: 9657003
    Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: May 23, 2017
    Assignee: ORION CORPORATION
    Inventors: Gerd Wohlfahrt, Olli Törmäkangas, Harri Salo, Iisa Höglund, Arja Karjalainen, Pia Koivikko, Patrik Holm, Sirpa Rasku, Anniina Vesalainen
  • PROTEIN KINASE INHIBITORS
    Publication number: 20160346254
    Abstract: A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.
    Type: Application
    Filed: August 9, 2016
    Publication date: December 1, 2016
    Inventors: Tero LINNANEN, Gerd WOHLFAHRT, Srinivas NANDURI, Ravi UJJINAMATADA, Srinivasan RAJAGOPALAN, Subhendu MUKHERJEE
  • Protein kinase inhibitors
    Patent number: 9447091
    Abstract: A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: September 20, 2016
    Assignee: ORION CORPORATION
    Inventors: Tero Linnanen, Gerd Wohlfahrt, Srinivas Nanduri, Ravi Ujjinamatada, Srinivasan Rajagopalan, Subhendu Mukherjee
  • NOVEL CYP17 INHIBITORS/ANTIANDROGENS
    Publication number: 20160130254
    Abstract: Compounds of formula (I) wherein R1 to R8, A, B, Z1, and Z2 are as defined in the claims and pharmaceutically acceptable salts and esters thereof are disclosed. The compounds of formula (I) possess utility as androgen receptor antagonists (inhibitors) and/or cytochrome P450 monooxygenase 17?-hydroxylase/17,20-lyase (CYP17) inhibitors. The compounds are useful as medicaments in the treatment of cancer, particularly prostate cancer, and other androgen dependent conditions and diseases where androgen antagonism is desired.
    Type: Application
    Filed: June 10, 2014
    Publication date: May 12, 2016
    Inventors: Gerd WOHLFAHRT, Petteri RUMMAKKO, Arja KARJALAINEN, Mikko PASSINIEMI, Pekka PIETIKÄINEN, Anssi HAIKARAINEN, Emilia VÄISÄNEN, Eija TIAINEN
  • ANDROGEN RECEPTOR MODULATING COMPOUNDS
    Publication number: 20150203479
    Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: January 16, 2015
    Publication date: July 23, 2015
    Inventors: Gerd WOHLFAHRT, Olli TÖRMÄKANGAS, Harri SALO, Iisa HÖGLUND, Arja KARJALAINEN, Pia KNUUTTILA, Patrik HOLM, Sirpa RASKU, Anniina VESALAINEN
  • Androgen receptor modulating compounds
    Patent number: 8975254
    Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: March 10, 2015
    Assignee: Orion Corporation
    Inventors: Gerd Wohlfahrt, Olli Törmäkangas, Harri Salo, Iisa Höglund, Arja Karjalainen, Pia Knuuttila, Patrik Holm, Sirpa Rasku, Anniina Vesalainen
  • PROTEIN KINASE INHIBITORS
    Publication number: 20150011548
    Abstract: A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.
    Type: Application
    Filed: October 9, 2012
    Publication date: January 8, 2015
    Inventors: Tero Linnanen, Gerd Wohlfahrt, Srinivas Nanduri, Ravi Ujjinamatada, Srinivasan Rajagopalan, Subhendu Mukherjee
  • Androgen receptor modulating carboxamides
    Patent number: 8921378
    Abstract: Compounds of formula (I) or (II) wherein Rx, Rz, R9, R10, R14, R14?, R15, R15?, A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: December 30, 2014
    Assignee: Orion Corporation
    Inventors: Olli Törmäkangas, Gerd Wohlfahrt, Harri Salo, Rathna Durga Ramasubramanian, Pranab Kumar Patra, Arputharaj Ebenezer Martin, Terhi Heikkinen, Anniina Vesalainen, Anu Moilanen, Arja Karjalainen
  • 2,3-dihydrobenzo[1,4] dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases
    Patent number: 8809536
    Abstract: Compounds of formula I wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: August 19, 2014
    Assignee: Orion Corporation
    Inventors: David Din Belle, Patrik Holm, Arto Karljalainen, Arto Tolvanen, Gerd Wohlfahrt, Petteri Rummakko
  • 2,3-DIHYDROBENZO[1,4] DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES
    Publication number: 20140179926
    Abstract: Compounds of formula I wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.
    Type: Application
    Filed: February 27, 2014
    Publication date: June 26, 2014
    Applicant: ORION CORPORATION
    Inventors: David DIN BELLE, Patrik HOLM, Arto KARLJALAINEN, Arto TOLVANEN, Gerd WOHLFAHRT, Petteri RUMMAKKO
  • 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases
    Patent number: 8697723
    Abstract: Compounds of formula I wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: April 15, 2014
    Assignee: Orion Corporation
    Inventors: David Din Belle, Patrik Holm, Arto Karljalainen, Arto Tolvanen, Gerd Wohlfahrt, Petteri Rummakko
  • ANDROGEN RECEPTOR MODULATING CARBOXAMIDES
    Publication number: 20140094474
    Abstract: Compounds of formula (I) or (II) wherein Rx, Rz, R9, R10, R14, R14?, R15, R15?, A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.
    Type: Application
    Filed: April 20, 2012
    Publication date: April 3, 2014
    Applicant: ORION CORPORATION
    Inventors: Olli Törmakängas, Gerd Wohlfahrt, Harri Salo, Rathna Durga Ramasurbamanian, Pranab Kumar Patra, Arputharaj Ebenezer Martin, Terhi Heikkinen, Anniina Vesalainen, Anu Moilanen, Arja Karjalainen
  • 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEM DISEASES
    Publication number: 20130281486
    Abstract: Compounds of formula I wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.
    Type: Application
    Filed: June 14, 2013
    Publication date: October 24, 2013
    Inventors: David DIN BELLE, Patrik HOLM, Arto KARLJALAINEN, Arto TOLVANEN, Gerd WOHLFAHRT, Petteri RUMMAKKO
  • 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous systeme diseases
    Patent number: 8492549
    Abstract: Compounds of formula I wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: July 23, 2013
    Assignee: Orion Corporation
    Inventors: David Din Belle, Patrik Holm, Arto Karljalainen, Arto Tolvanen, Gerd Wohlfahrt, Petteri Rummakko
  • ANDROGEN RECEPTOR MODULATING COMPOUNDS
    Publication number: 20120225867
    Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: October 27, 2010
    Publication date: September 6, 2012
    Inventors: Gerd Wohlfahrt, Olli Törmäkangas, Harri Salo, lisa Höglund, Arja Karjalainen, Pia Knuuttila, Patrik Holm, Sirpa Rasku, Anniina Vesalainen